Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in PCD pharma franchise in Hyderabad

Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in pharmaceutical manufacturing company in Mumbai

Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in cardiac care pharma franchise in Pune

Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in pharma suppliers in Delhi

Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in pharma export companies in Kolkata
Telmisartan 40mg + Cilnidipine 10mg + Metoprolol 25mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /telmisartan-cilnidipine-ip-10mg-metoprolol-ip-25mg-tablet

Telbolife Trio 25 Tablet

Composition : Telmisartan IP 40mg + Cilnidipine IP 10mg + Metoprolol IP 25mg

Dosage Form : Tablet

Packaging Type : Alu ALu

Packaging : 10x15

Price : ₹199/-

Telbolife Trio 25 Tablet is a fixed-dose combination used in the effective management of hypertension (high blood pressure) and cardiovascular risk reduction. It contains Telmisartan, an angiotensin II receptor blocker (ARB) that relaxes blood vessels; Cilnidipine, a calcium channel blocker that lowers blood pressure by preventing calcium influx in blood vessel walls; and Metoprolol Succinate, a cardio-selective beta-blocker that reduces heart rate and myocardial oxygen demand. This triple-drug combination offers synergistic control of blood pressure, improved arterial compliance, and protection against heart-related complications.

Read More

About the Product

Telbolife Trio 25 Tablet is a fixed-dose combination used in the effective management of hypertension (high blood pressure) and cardiovascular risk reduction. It contains Telmisartan, an angiotensin II receptor blocker (ARB) that relaxes blood vessels; Cilnidipine, a calcium channel blocker that lowers blood pressure by preventing calcium influx in blood vessel walls; and Metoprolol Succinate, a cardio-selective beta-blocker that reduces heart rate and myocardial oxygen demand. This triple-drug combination offers synergistic control of blood pressure, improved arterial compliance, and protection against heart-related complications.

Common side effects may include dizziness, fatigue, headache, slow heart rate, swelling of ankles (edema), or gastrointestinal discomfort. Rarely, it may cause hypotension, electrolyte imbalance, or liver function disturbances. Patients should seek immediate medical advice if they experience symptoms like persistent cough, chest pain, or severe dizziness.

Telbolife Trio 25 Tablet is indicated for the treatment of essential hypertension, particularly in patients who require a combination therapy for optimal blood pressure control. It is also beneficial in reducing cardiovascular events in hypertensive patients with coexisting conditions like diabetes, coronary artery disease, or left ventricular hypertrophy. The combination offers enhanced efficacy with improved patient adherence.

Should be used under medical supervision, especially in patients with liver, kidney, or heart disorders. Avoid abrupt discontinuation. Not recommended during pregnancy or lactation unless prescribed. Monitor blood pressure and heart rate regularly during treatment.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation